Cyclopharm rises on revenue outlook, U.S. FDA nod progress

Cyclopharm

04/07/2022 04:25

** Shares of radiopharmaceutical firm Cyclopharm  CYC.AX 
rise as much as 14.3% to A$1.16, their best intraday pct jump
since Sept. 16, 2021
    ** Says it expects A$11.3 million ($7.70 million) in total
unaudited group sales revenue over H1, a 36% increase
 urn:newsml:reuters.com:*:nASX60y7Kb 
    ** Adds that it has made "good progress" in the U.S. FDA
approval process for Technegas, its technology used to treat
lung diseases 
    ** On track for first commercial sales of Technegas in U.S.
in mid-2023 following FDA approval
    ** Stock hits highest level since June 14
    ** CYC down 38.1% YTD, as of last close 

($1 = 1.4680 Australian dollars)

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))